International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

Sandoz Launched Hyrimoz® (Adalimumab-adaz) High-concentration Formulation, Marking Sandoz Entrance into United States’ Immunology Space

Sandoz, a global leader in generic pharmaceuticals and biosimilars, announced earlier this month that the citrate-free high-concentration formulation (HCF) of its biosimilar Hyrimoz® (adalimumab-adaz) injection is now available in the United States starting July 1.

sando logo

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Categories

Recent Posts

IPC 2023 Think Tank Meeting Report Published in JID Innovations

Improving Medical Adherence in Psoriasis Treatments

Shining a Spotlight: Catching up with 2018 IPC Fellow Filip Rob, MD, PhD

Also Read

Press Release

Sotyktu™ (Deucravacitinib) Recommended by the National Institute for Health and Care Excellence (NICE) for use in England as a First-in-class Treatment Option for Moderate to Severe Plaque Psoriasis in Adults

Bristol Myers Squibb (BMS) announced last week that the National Institute for Health and Care Excellence (NICE) has recommended deucravacitinib, a once-daily oral tablet for use on the NHS in England as an option for treating certain adults with moderate to severe plaque psoriasis.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.